The forecast for the operating result is adjusted slightly downward, while the sales forecast is raised.
For the second quarter, the slimming giant reports an operating profit of 25.9 billion Danish kronor, which can be compared to 23.9 billion kronor last year. The expectations were at 27.3 billion kronor, according to analysts' forecasts.
Sales for the second quarter amounted to 68.1 billion Danish kronor, which can be compared to 54.3 billion kronor for the same period last year. The result was in line with expectations.
The sales of diabetes and obesity medicines Ozempic and Wegovy also fell short of expectations. The sales of Wegovy amounted to 11.7 billion Danish kronor in the second quarter. The expectations were at 13.7 billion Danish kronor.
Novo Nordisk, which is the highest-valued company in Europe, is a world leader in medicines for the treatment of diabetes and obesity.
